This is What Merck & Co. (MRK) is Doing to Mitigate Against KEYTRUDA Exclusivity Loss [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Conference, Merck & Co., Inc. (NYSE:MRK) unveiled strategic initiatives to mitigate the loss of exclusivity of its blockbuster drug, KEYTRUDA. The company expects a shallow dip in revenues from the flagship drug as its exclusivity ends. This is What Merck & Co., Inc. (MRK) is Doing To Mitigate Against KEYTRUDA Exclusivity Loss The strategic initiatives focus on innovation to transform the current portfolio through new products. The company is already expanding its oncology pipeline while also exploring new treatment options in cardiovascular and other therapeutic areas. Some of the new products slated for launch include WINREVAIR, OHTUVAYRE, CAPVAXIVE, INFLUENZA, and QULEX. MK-1406 clinical trials for influenza prevention are ongoing in the Southern Hemisphere, while V940, a neoantigen therapy, is under development, with a melanoma readout expected in 2028. It is also working on MK-3000, which targets patients with diabetic macular edema and neovascular AMD. Merck is also deve
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in DogsBusiness Wire
- FTC monitoring how drug companies react to patent cliff, official says 1 / 4 Dan Guarnera answers questions posed by Reuters Antitrust Correspondent Jody Godoy at Reuters Pharma USA in Philadelphia Dan Guarnera, who leads antitrust enforcement at the U.S.Acquire Media Monitor
- FTC monitoring how drug companies react to patent cliff, official says [Yahoo! Finance]Yahoo! Finance
- Imfinzi EU Approval Expands AstraZeneca Gastric Cancer Reach For Investors [Yahoo! Finance]Yahoo! Finance
- Yahoo Finance [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 3/12/26 - Form 3
- 2/24/26 - Form 10-K
- 2/17/26 - Form 13F-HR
- MRK's page on the SEC website